Diagnóstico y tratamiento de la EPOC

1. Agusti A, Chen R, Criner G, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. Global Initiative for Chronic Obstructive Lung Disease; 2018.

2. Wheaton AG, Cunningham TJ, Ford ES, Croft JB; Centers for Disease Control and Prevention (CDC). Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013. MMWR Morb MortalWkly Rep. 2015;64(11):289-295.

3. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143(5):1395-1406. doi:10.1378/chest.12-1135

4. Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017;(293):1-8.

5. Yawn B, Kim V. COPD in primary care: key considerations for optimized management: treatment options for stable chronic obstructive pulmonary disease: current recommendations and unmet needs. J Fam Pract. 2018;67(2)(suppl):S28-S37.

6. ZuWallack R. How are you doing? what are you doing? differing perspectives in the assessment of individuals with COPD. COPD. 2007;4(3):293-297.doi:10.1080/15412550701480620

7. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic bstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704-711. doi:10.1016/S0140-6736(09)61301-5

8. Mahler DA,Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580-586. doi:10.1378/chest.93.3.580

9. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009; 34(3):648-654. doi:10.1183/09031936.00102509

10. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873-884. doi:10.1183/09031936.00025214

11. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374(9691):733-743. doi:10.1016/S0140-6736(09) 61303-9

12. Krishnan JK, Martinez FJ. Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps. Curr Opin Pulm Med. 2018;24(2):124-129. doi:10.1097/MCP.0000000000000456

13. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935-945. doi:10.1016/S2213-2600(17)30434-4

14. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62(3):237-241. doi:10.1136/thx.2006.068379

15. US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(13):1372-1377. doi:10.1001/jama.2016.2638

16. Lal S, Ferguson AD, Campbell EJ. Forced expiratory time: a simple test for airways obstruction. BMJ. 1964;1(5386):814-817. doi:10.1136/bmj.1.5386.814

17. MiravitllesM, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610. doi:10.1183/13993003.00610-2017

18. Hurley K, O’Connor GT. Serum α1-antitrypsin concentration in the diagnosis of α1-antitrypsin deficiency. JAMA. 2018;319(19):2034-2035. doi:10.1001/jama.2018.3888

19. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2016;9:CD007851. doi:10.1002/14651858.CD007851.pub3.

20. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873

21. Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as predictors of lung cancer. Chest. 2018;153 (6):1326-1335. doi:10.1016/j.chest.2018.01.049ç

22. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007;132(6):1932-1938. doi:10.1378/chest.07-1490

23. Rothnie KJ, Mullerova H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464-471. doi:10.1164/rccm.201710-2029OC

24. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138. doi:10.1056/NEJMoa0909883

25. Guerra B, Haile SR, Lamprecht B, et al; 3CIA collaboration. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Med. 2018;16(1):33. doi:10.1186/s12916-018-1013-yç

26. van Eerd EAM, Risor MB, van Rossem CR, van Schayck OCP, Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease—a qualitative analysis. BMC FamPract. 2015;16:164.doi:10.1186/s12875-015-0382-y

27. Kopsaftis Z,Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;6:CD002733. doi:10.1002/14651858.CD002733.pub3

28. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged_65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb MortalWkly Rep. 2014;63(37):822-825.

29. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest. 1994;105(5):1411-1419. doi:10.1378/chest.105.5.1411

30. Qaseem A, Wilt TJ,Weinberger SE, et al; American College of Physicians. American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191. doi:10.7326/0003-4819-155-3-201108020-00008

31. Yawn BB, Thomashaw B, Mannino DM, et al. The 2017 update to the COPD foundation COPD pocket consultant guide. Chronic Obstr Pulm Dis (Miami). 2017;4(3):177-185. doi:10.15326/jcopdf.4.3. 2017.0136

32. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(7):CD009285. doi:10.1002/14651858.CD009285.pub3

33. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;(3):CD010844. doi:10.1002/14651858.CD010844.pub2

34. Kew KM, Mavergames C,Walters JAE. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177. doi:10.1002/14651858. CD010177.pub2

35. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15-25. doi:10.1136/thoraxjnl-2014-206732

36. Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907-922. doi:10.2147/COPD.S130482

Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease Review Clinical Review & Education jama.

37. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD003794. doi:10.1002/14651858.CD003794.pub4

38. Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388. doi:10.1136/bmj.k4388

39. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;9: CD002309. doi:10.1002/14651858.CD002309.pub5

40. Albert RK, Connett J, BaileyWC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698. doi:10.1056/NEJMoa1104623

41. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(9):CD009157. doi:10.1002/14651858.CD009157.pub2

42. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181-1196. doi:10.1016/j.chest.2016.02.646

43. Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017; 49(5):1602245. doi:10.1183/13993003.02245-2016

44. WangM-T, Liou J-T, Lin CW, et al.  Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229-238. doi:10. 1001/jamainternmed.2017.7720

45. Goto T, Shimada YJ, Faridi MK, Camargo CA Jr, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33(9):1461-1468. doi:10.1007/s11606-018-4518-3

46. Lipson DA, Barnhart F, Brealey N, et al. IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med.

2018;378(18):1671-1680. doi:10.1056/NEJMoa1713901

47. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391 (10125):1076-1084. doi:10.1016/S0140-6736(18)30206-X